Merit Medical Systems has officially launch its Interventional cardiac resynchronisation therapy initiative during the Heart Rhythm Society (HRS) Meeting in San Francisco, USA.
According to a company release, a growing body of evidence suggests that interventional cardiac resynchronisation therapy is associated with an increased ability to manage difficult anatomy, shorter case times, less radiation exposure to the operator and more optimal placement of the left ventricle lead.
Seth J Worley says, “The interventional approach for these procedures provides benefits for the physician, and more importantly, for the patient. Both my own experience and the clinical data have demonstrated increased optimal left ventricle lead placement, a reduction in lead implant failure rates, and a reduction in fluoroscopy, which results in shorter procedural times.”
During the meeting, Merit unveiled recently launched products, specifically designed for use in interventional cardiac resynchronisation therapy procedures, including the LVI 5.5, a tool designed reach to smaller distal target vessels, and the Hydrophilic Prelude Snap Splittable Sheath Introducer, which has a coating that is designed to reduce catheter insertion force by 50%.